Knownwell expands with 6 new Chicago locations, adding to existing Boston and Dallas clinics. CEO reports 78% virtual visits.
Agios' Pyrukynd met primary endpoint in Phase 3 study for children with PK deficiency who don't need regular transfusions, ...
The Senate on Thursday confirmed Robert F. Kennedy Jr. as secretary of Health and Human Services, putting a longtime ...
In a surprise move Thursday, Neumora remade its executive team and brought back its former CEO, following last month's ...
Sanofi faces $250M charge after E. coli vaccine developed with J&J fails Phase 3 trial; study ends early due to insufficient ...
Idorsia’s plan to hand over the global rights to its blood pressure drug Tryvio has ended in disappointment after a deal announced in November fell through.
An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities ...
New research from the University of North Carolina-Chapel Hill found that Novo Nordisk’s weight loss drug may help ...
CVS Health ended 2024 as it started, with high medical costs in the company’s insurance business chipping away at its bottom ...
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is ...
Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback